Ibida 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Treatment of bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase and exerts bactericidal action against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- For traveler's diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years of age)
- For hepatic encephalopathy: 550 mg 2 times daily (patients ≥18 years of age)
- For bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days (can be taken with or without food)
Interaction
In vitro study suggests Ibida induces CYP3A4, but not expected in patients with normal liver function at recommended dosage.
Contraindications
Hypersensitivity to Rifaximin or rifamycin antimicrobial agents, or any components of the product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Reactions including anaphylaxis, angioneurotic edema, and exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. Unknown excretion in human milk.
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in stools
- Discontinue if diarrhea symptoms worsen or persist for more than 24-48 hours
- Pseudomembranous colitis may occur and should be considered in patients with diarrhea post-antibacterial administration
Use in Special Populations
- Renal Impairment: Pharmacokinetics not studied
- Hepatic Impairment: Markedly elevated systemic exposure in hepatically impaired patients
Overdose Effects
No specific information on treatment. Discontinue, treat symptomatically, and institute supportive measures
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C, away from light & moisture. Keep out of reach of children.